SCHEMBL15317795

SCHEMBL15317795

CN(C)C1CCN(C(=O)c2ccc(N=[N+]=[N-])cc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL3 Q96JM7 11/20 0.71
▸ L3MBTL1 Q9Y468 8/20 0.62
▸ HDAC4 P56524 1/20 0.48
▸ MBTD1 Q05BQ5 4/20 0.44
▸ TP53BP1 Q12888 1/20 0.44
▸ L3MBTL4 Q8NA19 1/20 0.44
▸ HRH3 Q9Y5N1 2/20 0.43
▸ MKNK1 Q9BUB5 1/20 0.43
▸ MKNK2 Q9HBH9 1/20 0.43
▸ PIK3CD O00329 1/20 0.42
▸ PIK3C2B O00750 1/20 0.42
▸ PIK3CA P42336 1/20 0.42
▸ PIK3CB P42338 1/20 0.42
▸ MTOR P42345 1/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ PIK3C3 Q8NEB9 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15372706 0.83 L3MBTL3 (0.79) L3MBTL3L3MBTL1HDAC4MBTD1TP53BP1
SCHEMBL19127245 0.80 L3MBTL3 (0.43) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL10195702 0.79 L3MBTL3 (0.87) L3MBTL3L3MBTL1HDAC4MEN1KMT2A
SCHEMBL25498559 0.79 L3MBTL3 (0.87) L3MBTL3L3MBTL1HDAC4MBTD1TP53BP1
SCHEMBL19126810 0.78 L3MBTL3 (0.46) L3MBTL3L3MBTL1HDAC4MBTD1TP53BP1
SCHEMBL19127153 0.78 L3MBTL3 (0.46) L3MBTL3L3MBTL1HDAC4MBTD1TP53BP1
SCHEMBL19126808 0.78 L3MBTL3 (0.46) L3MBTL3L3MBTL1HDAC4MBTD1TP53BP1
SCHEMBL17271879 0.77 L3MBTL3 (0.84) L3MBTL3L3MBTL1HDAC4MBTD1TP53BP1
SCHEMBL3399465 0.77 L3MBTL3 (0.84) L3MBTL3L3MBTL1HDAC4MBTD1TP53BP1
SCHEMBL26773746 0.77 L3MBTL3 (0.84) L3MBTL3L3MBTL1HDAC4MBTD1TP53BP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 — — EP disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 — — US disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 — — US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 — — US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES NFATC1, IL5, CD4 L3MBTL3 4428/4885L3MBTL1 4489/4885HDAC4 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback